



## Antimicrobial Stewardship and Prescribing Practice

Guest Editor:

**Dr. Andreas A. Von Ameln-  
Mayerhofer**

Department of Clinical  
Pharmacy, Sindelfingen-  
Boeblingen Medical Center,  
71065 Sindelfingen, Germany

Deadline for manuscript  
submissions:

**closed (30 March 2024)**

### Message from the Guest Editor

Dear Colleagues,

Antimicrobial resistance is still a serious and growing problem in the treatment of severe infections. There are two main approaches to tackle this challenge: the development of novel substances which can bypass the resistance mechanisms, but also the continuous development of strategies to increase the adequate prescription of currently available antibiotics where they are needed. The last approach, i.e., antimicrobial stewardship strategies, is already well established in many countries and usually consists of a bundle of recommendations in order to improve the prescription practice and thus slow down the development of resistance. Among the recommendations communicated within antimicrobial stewardship programs or guidelines, the publication of local treatment guidelines and an antibiotics house list with concrete dosage recommendations are recommended for each hospital. This sounds like a clear and easy task but nevertheless requires teamwork among experts in practical reality and very often thorough consideration of advantages or disadvantages of different recommendations.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

## Contact Us

---

*Antibiotics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/antibiotics  
antibiotics@mdpi.com  
X@antibioticsmdpi